Loading...
Effects of rosuvastatin on postprandial leukocytes in mildly hyperlipidemic patients with premature coronary sclerosis.
Oostrom, A J H H M van Plokker, H W M Asbeck, B S van Rabelink, T J Kessel, K P M van Jansen, E H J M Stehouwer, C D A Cabezas, M Castro
Oostrom, A J H H M van
Plokker, H W M
Asbeck, B S van
Rabelink, T J
Kessel, K P M van
Jansen, E H J M
Stehouwer, C D A
Cabezas, M Castro
Citations
Altmetric:
Series / Report no.
Open Access
Type
Article
Language
en
Date of publication
2006-04-01
Year of publication
Files
Loading...
oostrom.pdf
Adobe PDF, 354.03 KB
Research Projects
Organizational Units
Journal Issue
Title
Effects of rosuvastatin on postprandial leukocytes in mildly hyperlipidemic patients with premature coronary sclerosis.
Translated Title
Published in
Atherosclerosis 2006; 185(2):331-9
Abstract
We investigated whether pro-inflammatory aspects of the postprandial phase can be modulated by rosuvastatin in premature coronary artery disease (CAD) patients. Herefore standardized 8 h oral fat loading tests were performed off-treatment and after rosuvastatin 40 mg/d in 20 male CAD patients (50 +/- 4 years). The expression of leukocyte activation markers CD11a, CD11b, CD62L and CD66b was studied using flowcytometry. Migration of isolated neutrophils towards chemoattractants was determined in a fluorescence-based assay. Rosuvastatin did not affect baseline leukocyte counts nor the postprandial neutrophil increment (maximum mean increase +10% pre- and +14% post-treatment, P < 0.01 for each). Rosuvastatin reduced baseline platelets (from 266 +/- 78 to 225 +/- 74 x 10(9) cells/L, P < 0.001) and blunted the postprandial platelet count change (maximum mean increase +6%, P = 0.01, and 0%, respectively). The baseline expression of CD11a, CD11b and CD62L increased on most types of leukocytes by rosuvastatin, whereas the postprandial responses were unaffected. Pretreatment, postprandial neutrophil migration increased dose-dependently, but there were no postprandial changes after rosuvastatin. The latter effect was unrelated to changes in lipoprotein concentrations. In conclusion, in CAD patients postprandial pro-inflammatory and pro-coagulant changes can be modified by rosuvastatin. These apparently lipid-lowering independent effects may render protection against atherosclerosis.